Does Rallies show Form 4 insider transactions for ZNTL?

Yes. Rallies tracks ZNTL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ZNTL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZNTL. It does not provide personalized investment advice.

ZNTL (Zentalis Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is a publicly traded Healthcare sector company. As of May 21, 2026, ZNTL trades at $3.59 with a market cap of $258.41M and a P/E ratio of -1.92. ZNTL moved +4.52% today. Year to date, ZNTL is +170.80%; over the trailing twelve months it is +189.84%. Its 52-week range spans $1.01 to $6.95. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces ZNTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ZNTL stock inside the company?

Recent ZNTL insider activity includes Vultaggio Vincent sold 6.89K, Bruns Ingmar sold 335, Vultaggio Vincent sold 3.38K, EASTLAND JULIA MARIE sold 889, and Bruns Ingmar sold 2.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ZNTL Key Metrics

Key financial metrics for ZNTL
Metric	Value
Price	$3.59
Market Cap	$258.41M
P/E Ratio	-1.92
EPS	$-1.91
Dividend Yield	0.00%
52-Week High	$6.95
52-Week Low	$1.01
Volume	52
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-137.06M
Gross Margin	0.00%

Recent ZNTL Insider Trades

Vultaggio Vincent sold 6.89K (~$16.70K) on Feb 10, 2026.
Bruns Ingmar sold 335 (~$801.622) on Feb 9, 2026.
Vultaggio Vincent sold 3.38K (~$8.09K) on Feb 9, 2026.
EASTLAND JULIA MARIE sold 889 (~$2.13K) on Feb 9, 2026.
Bruns Ingmar sold 2.96K (~$7.20K) on Feb 6, 2026.

Latest ZNTL News

Zentalis Selects 400mg QD 5:2 Dose, Q1 Cash at $212M — May 12, 2026
Zentalis Doses First Patient in Phase 3 ASPENOVA Trial for Cyclin E1 Ovarian Cancer — May 5, 2026
Zentalis to Present Azenosertib-Paclitaxel Phase 1b Data for Platinum-Resistant Ovarian Cancer — Apr 21, 2026
Azenosertib Induces 87.5% Complete Responses in TNBC Models; Ovarian Time To Next Treatment at 13.2 Months — Apr 17, 2026
Zentalis Selects 400mg QD 5:2 Dose After Superior DENALI Part 2a Results — Apr 9, 2026

ZNTL Analyst Consensus

7 analysts cover ZNTL: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.

Common questions about ZNTL

Who is trading ZNTL stock inside the company?: Recent ZNTL insider activity includes Vultaggio Vincent sold 6.89K, Bruns Ingmar sold 335, Vultaggio Vincent sold 3.38K, EASTLAND JULIA MARIE sold 889, and Bruns Ingmar sold 2.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ZNTL?: Yes. Rallies tracks ZNTL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ZNTL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZNTL. It does not provide personalized investment advice.